Advertisement
ENOV vs ZBH
Which Stock Would AI Choose? Enovis Corporation (ENOV) vs. Zimmer Biomet Holdings, Inc. (ZBH) Stock Comparison
Key Takeaways
- Both ENOV and ZBH are medical technology firms specializing in orthopedics, but ENOV's smaller market cap of $1.39 billion contrasts with ZBH's $17.7 billion, offering different risk-reward profiles.
- In recent market activity, ENOV has shown stronger short-term momentum with a 11.11% one-month gain, rebounding from yearly lows, while ZBH exhibits more stability amid robotics advancements.
- Analysts project significant upside for ENOV, with potential 100%+ gains cited, alongside insider buying, compared to mixed views on ZBH.
- ZBH benefits from established scale, a P/E ratio (price-to-earnings ratio) of 25.71, and growth in areas like robotic-assisted surgery, providing defensive qualities over ENOV's volatility.
- Recent weeks highlight ENOV's bargain valuation and upcoming Q1 2026 earnings, positioning it for potential catalysts against ZBH's steady dividend and buybacks.
Introduction
This stock comparison examines ENOV and ZBH, two players in the orthopedic medical technology sector. Investors seeking exposure to reconstructive and recovery solutions may find value in analyzing their relative performance, as both navigate sector headwinds like procedure volumes and innovation demands. Traders focused on momentum versus stability, or growth-oriented small caps against large-cap defensives, will benefit from insights into recent price behavior, analyst sentiment, and market positioning in the current environment.
ENOV Overview and Recent Performance
Enovis Corporation (ENOV) develops clinically differentiated orthopedic solutions across Prevention & Recovery and Reconstructive segments, including bracing, bone growth stimulators, and joint replacement implants. Trading around $24 with a 52-week range of $21–$37.85, the stock has faced yearly pressure but rebounded over 11% in the past month amid broader market rallies. Sentiment has improved due to insider purchases, analyst buy ratings with targets up to $39–$43, and perceptions of undervaluation despite fast-paced momentum. Upcoming Q1 2026 earnings on May 7 add anticipation, as recent weeks show cash flow turnaround signals influencing positive shifts.
ZBH Overview and Recent Performance
Zimmer Biomet Holdings, Inc. (ZBH) designs and markets orthopedic reconstructive products like knee/hip implants, sports medicine solutions, and robotic systems such as ROSA. At approximately $91, within a 52-week range of $85–$108, the shares reflect YTD gains of about 2% with a P/E of 25.71. Recent market activity features robotics milestones, share buybacks, and a Q1 dividend of $0.24, supporting stability amid mixed analyst adjustments. Growth in digital technologies and procedure recovery has driven sentiment, though daily fluctuations highlight sector pressures in recent weeks.
Trending AI Robots
Tickeron’s Trending AI Robots page curates 25 top-performing AI trading bots from over 350 available, selected by AI for suitability in current market conditions across stocks, ETFs, and crypto. These bots employ diverse strategies like trend analysis, corridor take-profit/stop-loss (TP/SL), and multi-ticker portfolios, with annualized returns ranging from 15% to 168%, win rates of 48–88%, and profit factors up to 11.7. Examples include semiconductor-focused agents on NVDA and SOXL, aerospace bots with 67%+ win rates, and leveraged ETF traders. Timeframes vary from intraday to multi-week, with built-in risk management for copy trading. Explore these high-conviction options to enhance your strategy.
Head-to-Head Comparison
In business models, ENOV balances prevention products like therapy devices with reconstructive implants, targeting diverse healthcare providers, while ZBH emphasizes large-scale reconstructive and robotic systems for surgeons and hospitals. Growth drivers differ: ENOV leverages undervalued positioning and M&A potential (mergers and acquisitions), versus ZBH’s established robotics and data platforms. Recent momentum favors ENOV’s rebound, but ZBH offers lower volatility as a large cap. Risk factors include ENOV’s higher beta and earnings sensitivity against ZBH’s scale buffers. Both share medtech sector exposure, yet ENOV garners stronger bullish sentiment via analyst upside projections.
Tickeron AI Verdict
Tickeron’s AI currently favors ENOV for traders eyeing relative outperformance, given its recent trend consistency, substantial analyst-implied upside, and catalysts like impending earnings amid a rebound trajectory. ZBH appeals more to stability-focused investors via its market position and robotics momentum, though probabilistic models highlight ENOV’s edge in the near-term market environment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ENOV is a StrongBuy and ZBH is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ENOV’s FA Score shows that 0 FA rating(s) are green whileZBH’s FA Score has 1 green FA rating(s).
- ENOV’s FA Score: 0 green, 5 red.
- ZBH’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ENOV’s TA Score shows that 2 TA indicator(s) are bullish while ZBH’s TA Score has 4 bullish TA indicator(s).
- ENOV’s TA Score: 2 bullish, 6 bearish.
- ZBH’s TA Score: 4 bullish, 5 bearish.
Price Growth
ENOV (@Medical/Nursing Services) experienced а +1.53% price change this week, while ZBH (@Medical/Nursing Services) price change was -1.33% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +0.45%. For the same industry, the average monthly price growth was -3.28%, and the average quarterly price growth was -15.87%.
Reported Earning Dates
ENOV is expected to report earnings on Jul 30, 2026.
ZBH is expected to report earnings on Aug 04, 2026.
Industries' Descriptions
@Medical/Nursing Services (+0.45% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| ENOV | ZBH | ENOV / ZBH | |
| Capitalization | 1.23B | 16.8B | 7% |
| EBITDA | -770.33M | 2.31B | -33% |
| Gain YTD | -20.045 | -2.884 | 695% |
| P/E Ratio | N/A | 22.56 | - |
| Revenue | 2.28B | 8.41B | 27% |
| Total Cash | 33.1M | 424M | 8% |
| Total Debt | 1.41B | 7.47B | 19% |
ENOV | ZBH | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 56 | 69 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 76 Overvalued | 9 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 99 | 83 | |
PRICE GROWTH RATING 1..100 | 64 | 55 | |
P/E GROWTH RATING 1..100 | 97 | 40 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ZBH's Valuation (9) in the Medical Specialties industry is significantly better than the same rating for ENOV (76) in the Industrial Machinery industry. This means that ZBH’s stock grew significantly faster than ENOV’s over the last 12 months.
ZBH's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as ENOV (100) in the Industrial Machinery industry. This means that ZBH’s stock grew similarly to ENOV’s over the last 12 months.
ZBH's SMR Rating (83) in the Medical Specialties industry is in the same range as ENOV (99) in the Industrial Machinery industry. This means that ZBH’s stock grew similarly to ENOV’s over the last 12 months.
ZBH's Price Growth Rating (55) in the Medical Specialties industry is in the same range as ENOV (64) in the Industrial Machinery industry. This means that ZBH’s stock grew similarly to ENOV’s over the last 12 months.
ZBH's P/E Growth Rating (40) in the Medical Specialties industry is somewhat better than the same rating for ENOV (97) in the Industrial Machinery industry. This means that ZBH’s stock grew somewhat faster than ENOV’s over the last 12 months.
| ENOV | ZBH | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 68% |
| Stochastic ODDS (%) | 2 days ago 64% | 2 days ago 67% |
| Momentum ODDS (%) | 2 days ago 76% | 2 days ago 67% |
| MACD ODDS (%) | 2 days ago 53% | N/A |
| TrendWeek ODDS (%) | 2 days ago 79% | 2 days ago 60% |
| TrendMonth ODDS (%) | 2 days ago 76% | 2 days ago 54% |
| Advances ODDS (%) | 19 days ago 61% | 19 days ago 64% |
| Declines ODDS (%) | 13 days ago 78% | 13 days ago 58% |
| BollingerBands ODDS (%) | N/A | 2 days ago 58% |
| Aroon ODDS (%) | 2 days ago 70% | 2 days ago 54% |
Advertisement
ENOV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ENOV has been loosely correlated with CNMD. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if ENOV jumps, then CNMD could also see price increases.
| Ticker / NAME | Correlation To ENOV | 1D Price Change % | ||
|---|---|---|---|---|
| ENOV | 100% | -3.05% | ||
| CNMD - ENOV | 57% Loosely correlated | -0.12% | ||
| FELE - ENOV | 56% Loosely correlated | +0.22% | ||
| DOV - ENOV | 55% Loosely correlated | +2.61% | ||
| PH - ENOV | 53% Loosely correlated | +0.93% | ||
| ITT - ENOV | 52% Loosely correlated | +1.23% | ||
More | ||||
ZBH and
Correlation & Price change
A.I.dvisor indicates that over the last year, ZBH has been loosely correlated with KIDS. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ZBH jumps, then KIDS could also see price increases.
| Ticker / NAME | Correlation To ZBH | 1D Price Change % | ||
|---|---|---|---|---|
| ZBH | 100% | -1.00% | ||
| KIDS - ZBH | 45% Loosely correlated | -3.66% | ||
| ENOV - ZBH | 45% Loosely correlated | -3.05% | ||
| CNMD - ZBH | 44% Loosely correlated | -0.12% | ||
| SYK - ZBH | 44% Loosely correlated | -1.01% | ||
| LIVN - ZBH | 44% Loosely correlated | +0.25% | ||
More | ||||